These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37772432)

  • 1. Analysis of clinicopathological characteristics and prognostic factors of early-stage human epidermal growth factor receptor 2 (HER2)-low breast cancer: Compared with HER2-0 breast cancer.
    Wu Q; Yang F; Liu Y; Zhang H; Zhang S; Xin L; Xu L
    Cancer Med; 2023 Oct; 12(19):19560-19575. PubMed ID: 37772432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
    Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors.
    de Gregorio A; Friedl TWP; Hering E; Widschwendter P; de Gregorio N; Bekes I; Janni W; Dayan D; Huober JB
    Oncology; 2021; 99(12):780-789. PubMed ID: 34535596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
    Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
    Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological Features and Long-Term Prognostic Role of Human Epidermal Growth Factor Receptor-2 Low Expression in Chinese Patients with Early Breast Cancer: A Single-Institution Study.
    Kong ZQ; Liu LQ; Huang Q; Wang YT; Li JJ; Zhang Z; Wang XX; Liu CL; Zhang YD; Shao JK; Zhu YM; Chen YM; Liu M; Zhao WH
    Biomed Environ Sci; 2024 May; 37(5):457-470. PubMed ID: 38843919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients.
    Chen Z; Jia H; Zhang H; Chen L; Zhao P; Zhao J; Fu G; Xing X; Li Y; Wang C
    Breast Cancer Res Treat; 2023 Nov; 202(2):313-323. PubMed ID: 37639064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
    Ilie SM; Briot N; Constantin G; Roussot N; Ilie A; Bergeron A; Arnould L; Beltjens F; Desmoulin I; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Amet A; Coutant C; Coudert B; Bertaut A; Ladoire S
    Breast Cancer; 2023 Nov; 30(6):997-1007. PubMed ID: 37561255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between Homologous Recombination Repair Defect Status and Long-Term Prognosis of Early HER2-Low Breast Cancer: A Retrospective Cohort Study.
    Chen J; Zhu Y; Wu W; Xu Y; Yang W; Ling L; Lin Q; Jia S; Xia Y; Liu Z; Yang Y; Gong C
    Oncologist; 2024 Jul; 29(7):e864-e876. PubMed ID: 38366907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter study of the clinicopathological characteristics and a risk prediction model of early-stage breast cancer with hormone receptor-positive/human epidermal growth factor receptor 2-low expression.
    Xin L; Wu Q; Zhan C; Qin H; Xiang H; Gao M; Duan X; Liu Y; Ye J; ;
    Chin Med J (Engl); 2023 Dec; 136(24):2967-2973. PubMed ID: 37822006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression and prognostic role of EBP1 and relationship with AR in HER2+ breast cancer.
    Liu J; Xu C; Xu D; Cao L; Xue H; Meng Q; Niu Y
    Virchows Arch; 2020 Aug; 477(2):279-289. PubMed ID: 32086588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer.
    Yue Y; Liang J; Wu Y; Tong W; Li D; Cao X; Wang X
    Technol Cancer Res Treat; 2022; 21():15330338221132669. PubMed ID: 36254567
    [No Abstract]   [Full Text] [Related]  

  • 13. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
    Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
    Harbeck N; Nitz UA; Christgen M; Kümmel S; Braun M; Schumacher C; Potenberg J; Tio J; Aktas B; Forstbauer H; Grischke EM; Scheffen I; Malter W; von Schumann R; Just M; Zu Eulenburg C; Biehl C; Kolberg-Liedtke C; Deurloo R; de Haas S; Jóźwiak K; Hauptmann M; Kates R; Graeser M; Wuerstlein R; Kreipe HH; Gluz O;
    J Clin Oncol; 2023 Aug; 41(22):3796-3804. PubMed ID: 36809046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
    Ergun Y; Ucar G; Akagunduz B
    Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
    Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
    Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021).
    Xin L; Wu Q; Zhan C; Qin H; Xiang H; Xu L; Ye J; Duan X; Liu Y;
    Chin Med J (Engl); 2022 Mar; 135(6):697-706. PubMed ID: 35274907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.